Introducing StarTric: Transcatheter tricuspid heart valve repair

Press Release

Amsterdam, 16/11/2023

StarTric is poised to revolutionize the treatment of tricuspid heart valve regurgitation with the first minimally invasive, transcatheter approach that replicates the Clover surgical technique.

Tricuspid regurgitation (TR) is a very serious and widespread cardiovascular disease. It results in reduced oxygenation of the whole body, seriously impacting quality of life and causing atrial fibrillation, heart failure, and high mortality. TR affects 0.4% of the total population and 4% of those above 75 years of age, totaling about 4 million patients in Europe and 70 million patients worldwide.

Open-heart surgery has historically proven effective but is applied to less than 3% of patients due to its high operational mortality rate of 9%. A few years ago, a first-generation of minimally invasive technologies, adapted from mitral applications, attempted to address untreated patients but has fallen short in clinical efficacy, leaving a significant therapeutic gap.

Addressing a Health Challenge

StarTric aims to meet this unmet need with its innovative approach. It is the first and only minimally invasive repair technology specifically designed for the tricuspid valve. Replicating the Clover technique, StarTric utilizes a tiny device adaptable to patient anatomy, implantable with a beating heart via a transfemoral catheter. This promises to deliver outcomes comparable to the Clover technique, addressing the vast population of TR patients.

Daniele Zanotti, CEO, and Eugenio Passanante, COO & CFO, lead StarTric. Daniele brings a strong background in science and business, having successfully launched technology start-ups in clinical areas like structural heart diseases. Eugenio contributes extensive experience in high-tech cardiac products distribution and venture finance, having led StarTric through feasibility and initial funding rounds.

About StarTric

Based in Italy with a global outlook, StarTric aims to establish itself as the standard-of-care for TR patients worldwide. Collaborating with key opinion leaders (KOLs) like Prof. Ottavio Alfieri and Prof. Michele De Bonis, co-founders of the Clover technique, StarTric combines clinical excellence with innovative technology.

Eugenio Passanante, COO & CFO, lead StarTric:

"With the support of NLC's network, StarTric is set for a new phase of growth... Our vision extends beyond clinical efficacy to democratizing treatment access and personalizing patient care."

Since its inception in 2020, StarTric has met feasibility requirements and successfully tested advanced prototypes on ex vivo and in vivo swine models, including pathological ones. The next phase involves finalizing product design freeze and proceeding with pre-clinical and clinical validation.

For More Information

Startric | Website

Daniele Zanotti | CEO | Linkedin

Via della Moscova 3, 20121 Milan - Italy